How Effective is Imbruvica, Know its Dosage, Side Effects?

The US Food and Drug Administration (FDA) had approved of the usage of imbruvica or ibrutinib to treat mantle cell lymphoma on an accelerated basis. Tumors do respond to imbruvica or ibrutinib treatment and has been proved clinically. However, it is unknown that imbruvica or ibrutinib can lengthen survival time or improve symptoms in people suffering from this kind of lymphoma.

It is important to follow all the guidelines that are written on the package and label of imbruvica or ibrutinib. It is equally important you tell your doctor about all your medical conditions and medications you are currently taking.

How Effective is Imbruvica?

How Effective is Imbruvica?

Imbruvica, also known as ibrutinib, is an effective medicine for cancer treatment which works to prevent the spread and growth of cancer cells throughout the body.

Imbruvica or ibrutinib is also effectively used for the treatment of different kinds of non-Hodgkin lymphoma, which also includes MCL (mantle cell lymphoma), small lymphocytic lymphoma (SLL), and chronic lumphocytic leukemia (CLL), Waldenstrom’s macroglobulinemia mainly in people having or not having 17p deletion

Imbruvica or ibrutinib is otherwise given to patients when other medicines for the cure do not have any impact in the body.

You Must Know these Details before Taking Imbruvica

If you are allergic to imbruvica or ibrutinib, do not take it. To make sure this medicine is safe for your body, tell your physician if you have any of these following medical conditions:

  • Liver disease
  • Heart rhythm disorder
  • Kidney disease
  • Any recent surgery
  • Heart disease risk factors (mainly smoking, high blood pressure, diabetes, high cholesterol, being overweight)
  • An active infection
  • Blood thinner intake (Coumadin, warfarin, Jantoven.)

Imbruvica or ibrutinib might increase the danger of causing other kinds of cancer in the body mainly skin cancer. Therefore, ask your physician about this specific risk.

If you are pregnant do not consume imbruvica or ibrutinib. This might cause dangers to the baby. Before starting this treatment, you must check for pregnancy test and results must be negative.

While using imbruvica or ibrutinib you must have very effective birth controls pills irrespective of your gender. When both parent have birth control pills it will cause birth defects. Therefore, even after 30 days of your final imbruvica or ibrutinib dosage, have the birth control pills.

It is unknown if imbruvica or ibrutinib passes through breast milk to the baby. While on this medicine do not breast feed your baby.

How to Take Imbruvica?

Follow the methods your doctor suggests in taking imbruvica or ibrutinib. You must follow all the guidelines mentioned in the package and prescriptions. Also, taking this medicine in smaller or larger amounts than what is recommended will cause harm.

  • Drink a lot of water while taking imbruvica or ibrutinib. You can take Imbruvica with a glass full of water.
  • This medicine is mostly taken one time in a day and it has to be taken at the same time every day.
  • Do not open, chew, crush, break the tablet instead swallow it as it is.

In case you need dental work or any surgery, it is important for you to tell your doctor ahead of time that you are on Imbruvica. You might have to cease taking this tablet for some time in order to complete the surgery.

This medicine has to be kept away from heat and moisture and stored at room temperature. The bottle has to be tightly closed especially when not used.

What is the Suggested Dosage of Imbruvica?

  1. General Adult Dosage of Imbruvica or Ibrutinib for Lymphoma Treatment

    Take this medicine one dosage a day orally 560 milligrams (4 x 140 milligrams capsules)

    Imbruvica or ibrutinib is effectively used to treat patients suffering from MCL (mantle cell lymphoma) especially those who received one therapy earlier.

  2. General Adult Dosage of Imbruvica or Ibrutinib for Chronic Lymphocytic Leukemia

    Take imbruvica or ibrutinib dosage one time a day orally 420 milligrams (3 x 140 milligrams capsules)

    Imbruvica or ibrutinib is effectively used to treat patients suffering from CLL (chronic lumphocytic leukemia) especially those who received one therapy earlier or condition CLL with 17p deletion.

What are the Side Effects of Imbruvica?

If you experience any allergic reactions to this medicine it is important to get immediate help. In most cases, allergic reactions experienced are swelling of lips, throat, face, tongue, difficulty in breathing, hives.

If you experience any of these conditions, kindly stop using imbruvica or ibrutinib and get immediate help from your doctor:

  • Ongoing or severe diarrhea.
  • Confusion, severe dizziness or weakness, prolonged headache, problems with speech is seen in imbruvica or ibrutinib.
  • Severe dizziness or chest pain, trouble breathing, irregular or fast heartbeats, feeling of fainting.
  • Easy bruising, red or purple pinpoint spots under skin, pale skin, abnormal bleeding from rectum, mouth, nose, and vagina.
  • Swollen gums, skin sores, painful mouth sores, fever, cough, difficulty in breathing, pain when swallowing, cold or flu symptoms;
  • Bleeding signs in your digestive tract which may be severe stomach ache, black or bloody stools, pink or brown urine or if you cough up vomit or blood similar to coffeegrounds;
  • Signs of breakdown of tumor cells like blood in your urine, lower back pain, muscle tightness or weakness, tingly sensation around your mouth or numbness, weak pulse, slow or fast heart rate.
  • Problems in kidney like little or no urinating, swelling in your ankles or feet, painful or difficult urination, short of breath or feeling tired.

Most of the common side effects of imbruvica or ibrutinib may include:

  • Easy bruising or bleeding, pale skin;
  • Chills, flu symptoms or fever;
  • Diarrhea, nausea;
  • Feeling tired;
  • Rash; or
  • Bone pain, muscle pain are also side effects of imbruvica or ibrutinib.
Pramod Kerkar, M.D., FFARCSI, DA
Pramod Kerkar, M.D., FFARCSI, DA
Written, Edited or Reviewed By: Pramod Kerkar, M.D., FFARCSI, DA Pain Assist Inc. This article does not provide medical advice. See disclaimer
Last Modified On:June 10, 2019

Recent Posts

Related Posts